Table 2.

Most significant not randomized second line studies

Ref.	Year study	Regimens	Patients	OS (mo)
Reni et al[22]	2006	Oxaliplatin + Raltitrexed	41	5.2
Demols et al[23]	2006	Oxaliplatin + Gemcitabine	33	6
Saif et al[25]	2010	Docetaxel	17	4
Yi et al[31]	2009	Irinotecan	33	6.6
Zaniboni et al[32]	2012	Folfiri	50	5
Bertocchi et al[40]	2015	Abraxane + gemcitabine	23	5

OS: Overall survival.